Skip to Content
Morningstar

Becton Dickinson & Co BDX

Morningstar Rating
Unlock
Stock XNYS Rating as of
$233.15 +0.94 (0.40%)
View Full Chart
As of Delayed Price Pre-Open: $233.15 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Becton, Dickinson Should See Normalization in 2024 With Alaris' Return

Alex Morozov

After a tumultuous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm's core business growth in the upcoming years as the testing revenue fades. As Alaris has now returned to the market, the last remaining uncertainty has been resolved, although it is still to be seen whether the damage experienced by the franchise will be long-lasting or whether Alaris can regain its market-leading share rapidly.

Read Full Report

Price vs Fair Value

View History
BDX is trading within a range we consider fairly valued.
Price
$233.15
Fair Value
$878.00
Uncertainty
Medium
1-Star Price
$337.24
5-Star Price
$498.20
Economic Moat
Slcgkkq
Capital Allocation
Cmwcbrk

Bulls Say, Bears Say

Bulls

The pharmaceutical business is the star of BD's portfolio. We expect robust growth to continue driven by demand for injectables.

Bears

BD's China medication delivery segment is facing competitive bidding challenges, which will pressure the overall growth in China in the upcoming years.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BDX is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$232.21
Day Range
$230.47–233.25
52-Week Range
$229.40–287.32
Bid/Ask
$231.14 / $235.56
Market Cap
$67.36 Bil
Volume/Avg
76 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
19.56
Price/Sales
3.47
Dividend Yield (Trailing)
1.60%
Dividend Yield (Forward)
1.63%
Total Yield
1.60%

Company Profile

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Core
Total Number of Employees
73,000
Website
https://www.bd.com

Competitors

Valuation

View More
Metric
BDX
MDT
RHHBY
Price/Earnings (Normalized)
 19.5614.6411.10
Price/Book Value
 2.662.035.52
Price/Sales
 3.473.262.89
Price/Cash Flow
 20.7514.4210.64
Price/Earnings
BDX
MDT
RHHBY

Financial Strength

Metric
BDX
MDT
RHHBY
Quick Ratio
 0.461.460.99
Current Ratio
 1.082.301.35
Interest Coverage
 4.178.8614.93
Quick Ratio
BDX
MDT
RHHBY

Profitability

Metric
BDX
MDT
RHHBY
Return on Assets (Normalized)
 3.40%7.75%17.03%
Return on Equity (Normalized)
 7.05%13.75%53.42%
Return on Invested Capital (Normalized)
 5.04%9.87%26.30%
Return on Assets
BDX
MDT
RHHBY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Instruments & Supplies Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncZdcmrzlpcFfy$132.1 Bil
ALC
Alcon IncYzsgzpyvHfxkh$39.1 Bil
CLPBY
Coloplast A/S ADRDdhjchbcqqQfn$28.8 Bil
WST
West Pharmaceutical Services IncZjmhztmdfQhg$27.6 Bil
RMD
ResMed IncKygdrhycRywzphx$26.1 Bil
BAX
Baxter International IncJjkmmnvYdxhym$20.1 Bil
COO
The Cooper Companies IncZhynrzpxyKtfwhw$18.0 Bil
HOLX
Hologic IncDblssgfJryzj$17.6 Bil
TFX
Teleflex IncRbxJnqjb$9.8 Bil

Sponsor Center